Investors

Press Releases

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

July 17, 2019

Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019   GENEVA, Switzerland and BOSTON, MA…

Read more

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

July 17, 2019

Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the…

Read more

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

July 17, 2019

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

July 17, 2019

Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna

June 21, 2019

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna   Geneva,…

Read more

ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

June 4, 2019

Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

May 16, 2019

Geneva, Switzerland and Boston, MA – May 16, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva Reports First Quarter 2019 Financial Results

May 9, 2019

2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids; MAA submission for nolasiban…

Read more

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

May 9, 2019

Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

May 8, 2019

Geneva, Switzerland and Boston, MA – May 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue